Dose-dependent pharmacokinetic interaction between antipyrine and paracetamol in vivo and in vitro when administered as a cocktail in pig

References

• Ameer B., Greenblatt D. J., Divoll M., Abernethy D. D., Skargel L. High-performance liquid chromatographic determination of acetaminophen in plasma: single dose pharmacokinetic studies. Journal of Chromatography and Biomedical Applications 1981; 226: 224–230
   Google Scholar
• Awni W. M., St Peter J. V., Kovarik J. M., Matzke G. R. Disposition of antipyrine and acetaminophen given alone and in combination to human subjects. Pharmaceutical Research 1990; 7: 204–207
   PubMed Web of Science ®Google Scholar
• Blyden G. T., Greenblatt D. J., LeDuc B. W., Scavone J. M. Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. European Journal of Clinical Pharmacology 1988; 35: 413–417
   PubMed Web of Science ®Google Scholar
• Bock K. W., Bock-Hennig B. S. Differential induction of human liver UDP-glucuronosyltransferase activities by phenobarbital-type inducers. Biochemical Pharmacology 1987; 36: 4137–4143
   PubMed Web of Science ®Google Scholar
• Bötcher J., Bässman H., Schüppel R. Quantitation and urinary pattern of 4,4′-dihydroxy-antipyrine, 4-hydroxy-antipyrine and 3-hydroxymethyl-antipyrine as main metabolites of antipyrine in man and rat. Journal of Pharmacy and Pharmacology 1982; 34: 168–175
   PubMedGoogle Scholar
• Broek, Van Den J. M., Tuenissen W. E., Breimer D. D. Induction of hexobarbital and antipyrine metabolism by rifampicin treatment in the pig. Drug Metabolism and Disposition 1981; 9: 541–544
   PubMedGoogle Scholar
• Danhof M., Breimer D. D. Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers. British Journal of Clinical Pharmacology 1979; 8: 529–537
   PubMed Web of Science ®Google Scholar
• Danhof M., Krom D. P., Breimer D. D. Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment. Xenobiotica 1979; 9: 695–702
   PubMed Web of Science ®Google Scholar
• Danhof M., Verbeek R. M. A., Van Boxtel C. J., Boeijinga K. J., Breimer D. D. Differential effects of enzyme induction on antipyrine metabolite formation. British Journal Clinical Pharmacology 1982; 13: 379–386
   PubMed Web of Science ®Google Scholar
• Knights K. M., Gourlay G. K., Hall P., Cousins M. J. The predictive value of changes in antipyrine pharmacokinetics in halothane and paracetamol induced hepatic necrosis in rats. Research Communications Chemical Pathology and Pharmacology 1983; 40: 199–215
   PubMedGoogle Scholar
• Kroemer H. K., Klotz U. Glucuronidation of Drugs. Clinical Pharmacokinetics 1992; 23: 292–310
   PubMed Web of Science ®Google Scholar
• Loft S. Metronidazole and antipyrine as probes for the study of foreign compound metabolism. Pharmacology and Toxicology 1990; 66(Suppl. VI)1–31
   PubMedGoogle Scholar
• Mansor S. M., Edwards G., Roberts P. J., Ward S. A. The effect of malaria infection on paracetamol disposition in the rat. Biochemical Pharmacology 1991b; 41: 1701–1711
   PubMedGoogle Scholar
• Mansor S. M., Ward S. A., Edwards G. The effect of malaria infection of antipyrine metabolite formation in the rat. Biochemical Pharmacology 1991a; 41: 1264–1266
   PubMed Web of Science ®Google Scholar
• Miners J. O., Adams J. F., Birkett D. J. A simple hplc assay for urinary paracetamol metabolites and its use to characterize the C3H mouse as a model for paracetamol metabolism studies. Clinical Experimental Physiology Pharmacology 1984; 11: 209–217
   PubMed Web of Science ®Google Scholar
• Miners J. O., Lillywhite K. J., Yoovathaworn K., Pongmarutai M., Birkett D. J. Characterization of paracetamol UDP-glucuronosyltransferase activity in human liver microsomes. Biochemical Pharmacology 1990; 40: 595–600
   PubMed Web of Science ®Google Scholar
• Mitchell J. R., Jollow D. J., Potter W. Z., Davis D. C., Gillette J. R., Brodie B. B. Acetaminophen-induced hepatic necrosis I. Role of drug metabolism. Journal of Pharmacology and Experimental Therapeutics 1973; 187: 185–194
   PubMed Web of Science ®Google Scholar
• Pijpers A., Noordhuizen-Stassen E. N., Goedegebuure S. A., Van Dobbenburgh O. A., Roosendaal M., Cornelissen A. H. M., Verheijsen J. H. M. Intravenous catheterisation of conventional pigs without application of antimicrobial agents. Veterinary Quarterly 1989; 11: 216–221
   PubMed Web of Science ®Google Scholar
• Rutten A. A. J. J. L., Falke H. E., Catsburgh J. F., Topp R., Blaauboer B. J., Van Holsteijn I., Doorn L., Van Leeuwen F. X. R. Interalaboratory comparison of total cytochrome P-450 and protein determinations in rat liver microsomes. Archives in Toxicology 1987; 61: 27–33
   PubMed Web of Science ®Google Scholar
• Sakai H., Kobayashi S., Hamada K., Iida S., Tanaka H., Akita E., Uchida E., Yasuhara H. The effects of diltiazem on hepatic drug metabolizing enzymes in man using antipyrine, trimethadione and debrisoquine as model substrates. British Journal of Clinical Pharmacology 1991; 31: 353–355
   PubMedGoogle Scholar
• Schellens J. H. M., Van Der Wart J. H. F., Brugman M., Breimer D. D. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans assessed by a cocktail design study. Journal of Pharmacology and Experimental Therapeutics 1989; 249: 638–645
   PubMed Web of Science ®Google Scholar
• Tephly T. R., Burchell B. UDP-glucuronosyltransferases: a family of detoxifying enzymes. Trends in Pharmacological Sciences 1990; 11: 276–279
   PubMed Web of Science ®Google Scholar
• Teunissen M. W. E., Joeres R. P., Vermeulen N. P. E., Breimer D. D. Influence of 9-hydroxyellipticine and 3-methylcholanthrene treatment on antipyrine metabolite formation in rats in vivo. Xenobiotica 1983b; 13: 223–231
   PubMed Web of Science ®Google Scholar
• Teunissen M. W. E., Van Den Meerburg-Torren J. E., Vermeulen N. P. E., Breimer D. D. Automated HPLC-determination of antipyrine and its main metabolites in plasma, saliva and urine, including 4,4′-dihydroxy-antipyrine. Journal of Chromatography and Biomedical Applications 1983a; 278: 367–378
   Google Scholar
• Vesell E. S. The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clinical Pharmacology and Therapeutics 1979; 26: 275–286
   PubMed Web of Science ®Google Scholar
• Vial T., Sauveur C., Descotes J. Influence of acetaminophen and antipyrine kinetics in rats. Fundamentals in Clinical Pharmacology 1990; 4: 79–83
   PubMedGoogle Scholar
• Witkamp R. F., Lohuis J. A. C. M., Nijmeijer S. M., Kolker H. J., Noordhoek J., Van Miert A. S. J. P. A. M. Species- and sex-related differences in the plasma clearance and metabolite formation of antipyrine. A comparative study in four animal species: cattle, goat, rat and rabbit. Xenobiotica 1991; 21: 1483–1492
   PubMed Web of Science ®Google Scholar